Daily Management Review

Warren Buffett invests in pharmaceutics


02/15/2018


American billionaire investor Warren Buffett invested $ 360 million in the purchase of shares in the Israeli pharmaceutical company Teva, which caused a revival in the stock market. Teva’s shares jumped in price by 11%, raising the quotes of other pharmaceutical companies.



thetaxhaven
thetaxhaven
Last night, Warren Buffett's investment company Berkshire Hathaway notified the American regulators (SEC) that it bought 18.9 million shares of the Israeli pharmaceutical company Teva for $ 358 million, thus adding this pharmaceutical producer to its investment portfolio. In addition, Warren Buffett increased his investments in Apple, buying another 31.2 million shares. It is reported that Berkshire almost completely got rid of IBM shares. Recall that if in the middle of last year it owned 37 million shares of this high-tech company, then by the end of the year the volume fell to 2 million.

Berkshire Hathaway’s notice to the SEC caused a noticeable stir in the business media and among investors. It has long been known that Warren Buffett prefers to buy small stakes in companies without focusing on any one company or sector. The high degree of diversification of the Berkshire Hathaway investment portfolio and the in-depth analysis of the companies' potential is one of the hallmarks of Warren Buffett's strategy, through which he was dubbed the "investment guru". That's why every Buffett investment decision, especially related to adding new companies to the portfolio or removing shares from other companies, causes an instant reaction of the stock market. This time, the news that Warren Buffett added shares of the large pharmaceutical manufacturer to Berkshire's portfolio, led Teva shares to jump in price by 11%. In addition, Buffett's interest in the pharmaceutical company has also provoked optimism among investors in other large companies in this sector - Novartis, AstraZeneca, Takeda, Sanofi and many other large pharmaceutical corporations' quotations increased by 1.2-2.3%.

At the same time Buffett's bid for the pharmaceutical market cannot be called unexpected. In late January, Berkshire Hathaway, along with JP Morgan and Amazon, announced plans to establish a joint company that will carry out research and development in the field of health. It was reported that the activities of this joint company will be aimed not at making profits and doing business, but at reducing the costs of maintaining the health and treatment of employees of the three companies, which employ about 1.1 million people in total. "The rising prices for medicine in the US behave like insatiable worms, biting into our economy," Warren Buffett said at the time. "So far, we cannot offer an explicit answer to this problem. However, we do not want to put up with this as something inevitable. We want to find together a solution that would provide talented people with quality medical services, while keeping the costs of these services under control. "

source: cnn.com
 






Science & Technology

Amazon’s Ring gets in a privacy scandal

Facebook Is Creating A Stablecoin For Its WhatsApp Users

IBM offers to use the first quantum computer

Passport Numbers Of 5 Million Customers Hacked: Concedes Marriott

China Lifts Approval Freeze On New Video Games Launch

Concentrated Solar Plant System To Dispatch Electricity To The Grid On Demand

Unique Underground Transportation Tunnel Revealed By Elon Musk

Toyota is trying to revive demand for Prius

Deloitte: Smart speakers will show record sales in 2019

China takes the lead in quantum cryptography

World Politics

World & Politics

Macedonia ignites political crisis in Greece

Brazil turns right

Merkel’s Pledge Of A United Germany in 2019

Murder Suspects Of Jamal Khashoggi Put On Trial By Saudi Arabia

Japan is trying to save its population with robots and migrants

Germany closes the last coal mine

US launches investigation against Airbus

European regions with the most polluted air